International application No.
PCT/JP2004/014207

A.	CLASSI	FICATION	OF SUBJECT	MATTER

Int.Cl<sup>7</sup> C12N15/09, A61K45/00, A61P1/16, A61P11/06, A61P31/12, A61P31/14, A61P35/00, A61P37/04, A61P37/06, A61P37/08, C07K14/705, C07K16/28, C12N1/15, C12N1/19, C12N1/21, C12N5/00,

According to International Patent Classification (IPC) or to both national classification and IPC

#### B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Int.Cl<sup>7</sup> C12N15/09, A61K45/00, C07K14/705, C07K16/28, C12N1/15, C12N1/19, C12N1/21, C12N5/00, C12P21/02, C12Q1/02, G01N33/15, G01N33/50

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
CA/MEDLINE/BIOSIS/EMBASE/BIOTECHABS/WPIDS (STN),
GenBank/EMBL/DDBJ/GeneSeq, SwissProt/PIR/GeneSeq

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
х	EP 1201681 A (Millennium Pharmaceuticals, Inc.), 02 May, 2002 (02.05.02), Full text; Seq. ID. Nos. 6, 34 & US 2003175890 A	1-10,14,19, 2O
P,X	WO 03/89624 A (UAB RESEARCH FOUNDATION), 30 October, 2003 (30.10.03), Full text; Seq. ID. Nos. 27, 28 (Family: none)	1-7,19,20

Further documents are listed in the continuation of Box C.	See patent family annex.
Special categories of cited documents;     document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E" earlier application or patent but published on or after the international filing date  "L" document which may throw doubts on priority claim(s) or which is	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
cited to establish the publication date of another citation or other special reason (as specified)  "O" document referring to an oral disclosure, use, exhibition or other means document published prior to the international filing date but later than the priority date claimed	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art  "&" document member of the same patent family
Date of the actual completion of the international search 15 October, 2004 (15.10.04)	Date of mailing of the international search report 02 November, 2004 (02.11.04)
Name and mailing address of the ISA/ Japanese Patent Office	Authorized officer
Facsimile No.	Telephone No.

International application No.

PCT/JP2004/014207 Box No. I Nucleotide and/or amino acid sequence(s) (Continuation of item1.b of the first sheet) 1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, the international search was carried out on the basis of: type of material a sequence listing table(s) related to the sequence listing format of material in written format in computer readable form time of filing/furnishing contained in the international application as filed filed together with the international application in computer readable form furnished subsequently to this Authority for the purposes of search In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished. 3. Additional comments:

International application No.

PCT/JP2004/014207

Box No. II C	Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)
1. Claims N	earch report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:  os.:  hey relate to subject matter not required to be searched by this Authority, namely:
because the extent that Concerni 11 to 13 a by the des 6 and discons.	tos.: 11-13, 15-18  they relate to parts of the international application that do not comply with the prescribed requirements to such an at no meaningful international search can be carried out, specifically:  Ing the ligand, the agonist and the antagonist according to claims and 15 to 18, it is impossible to find anything that is supported scription in the meaning within Patent Corporation Treaty Article closed in the description in (continued to extra sheet)  Tos.:  They are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box No. III O	Observations where unity of invention is lacking (Continuation of item 3 of first sheet)
Aprotein by SEQ ID amino acid in common in protein. the priori Japanese to cell recept defined in Therefor 1. As all requestions.  2. X As all sear any additional As only so	Searching Authority found multiple inventions in this international application, as follows: In as set forth in claim 1 comprising an amino acid sequence represented NO:2 or 4 and the protein as set forth in claim 1 comprising the sequence represented by SEQ ID NO:6 have no novel chemical structure out are common to each other exclusively in being an NK cell receptor However, NK cell receptor proteins had been publicly known before ty date of the present case as reported in No.2003-527105 Published translation of PCT international publication. Thus, being an NK otor protein cannot be considered as a special technical matter as in Patent Cooperation Treaty Rule 13.3. The, it does not appear that there (continued to extra sheet) uired additional search fees were timely paid by the applicant, this international search report covers all searchable chable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of onal fee. The protein cannot be searched without effort justifying an additional fee, this Authority did not invite payment of onal fee. The protein cannot be searched without effort justifying an additional fee, this Authority did not invite payment of onal fee. The protein cannot be searched without effort justifying an additional fee, this Authority did not invite payment of onal fee. The protein cannot be considered as a special technical matter as the protein cannot be considered as a special technical matter as the protein cannot be considered as a special technical matter as the protein cannot be considered as a special technical matter as the protein cannot be considered as a special technical matter as the protein cannot be considered as a special technical matter as the protein cannot be considered as a special technical matter as the protein cannot be considered as a special technical matter as the protein cannot be considered as a special technical matter as the protein cannot be considered as a special technical matter as the protein cannot be
·	ed additional search fees were timely paid by the applicant. Consequently, this international search report is to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark on Protes	The additional search fees were accompanied by the applicant's protest.  No protest accompanied the payment of additional search fees.

International application No.
PCT/JP2004/014207

# Continuation of A. CLASSIFICATION OF SUBJECT MATTER (International Patent Classification (IPC))

Int.Cl7 C21P21/02, C12Q1/02, G01N33/15, G01N33/50

(According to International Patent Classification (IPC) or to both national classification and IPC)

Continuation of Box No.II-2 of continuation of first sheet(2) the meaning within Patent Corporation Treaty Article 5.

## Continuation of Box No.III of continuation of first sheet(2)

is a technical relationship between the inventions of the parts relating to a protein as set forth in claim 1 comprising an amino acid sequence represented by SEQ ID NO:2 or 4 and the inventions of the parts relating to the protein as set forth in claim 1 comprising the amino acid sequence represented by SEQ ID NO:6, among the inventions as set forth in claims 1 to 20, involving one or more of the same or corresponding special technical features. Thus, these groups of inventions are not considered as being so linked as to form a single general inventive concept.

Such being the case, the present international application does not comply with the requirement of unity of invention.